KAT6A overexpression and MDSCs recruitment are closely associated with a poor prognosis for patients with breast cancer.[7, 15, 20, 49] To further determine the clinical relevance of our findings in this study, we examined expression of KAT6A, SMAD3‐K20ac, SMAD3‐K117ac, MDSCs marker CD11b, T cell markers CD4 and CD8 in metastatic lymph nodes from 108 clinical TNBC specimens using IHC analysis. The gene discussed is SMAD3; the disease is breast cancer.